PubMed Health⌕ Search

Biomedical subjects

W Elinck

Publications and source records attributed to W Elinck.

9 recordsLinked to original sources

Intravenous versus nebulized terbutaline in patients with acute severe asthma; a double-blind randomized study.

Twenty-three patients with acute severe asthma were treated in a randomized double-blind way by either intravenous terbutaline two times at an hour interval 6 micrograms/kg or inhaled terbutaline two times 0.1 mg/kg. Peak expiratory flow rate in percent of expected value rose from 89 L/min to 128 L/min (P less than .01) in the intravenous group and from 97 L/min to 122 L/min (P less than .02) in the inhalation group; this was comparable for both groups. PaO2 initially was 7.55 kPa in the intravenous group and rose by 1.4 after 60 minutes (P less than .02) and by 1.33 after 120 minutes (P less than .01). The mean PaO2 did not change in the inhalation group. The pulse rate and blood pressure did not vary significantly in either of the two groups. We conclude that both the intravenous and inhalational administration of terbutaline are effective in acute severe asthma, but that the intravenous route is possibly better for increasing PaO2.

Acute Disease↗

A comparison of the clinical and bronchodilating effects of plain and slow-release tablets of terbutaline at steady state.

The clinical efficacy, the bronchodilating effect and the side effects of two oral forms of terbutaline were compared in a double-blind, cross-over study involving ten patients with chronic reversible airways obstruction. The administration of plain-tablets, containing 2.5 mg terbutaline sulphate, three times daily at 6 h intervals was compared to the administration of slow-release (SR) tablets, containing 5 mg terbutaline sulphate, every 12 h. Each course of treatment lasted for 7 days. Treatment with SR-tablets resulted in significantly higher lung function values in the morning (PEFR at home and FEV1 at the lung function laboratory on day 7). There were no significant differences between the two forms with regard to symptom score, extra use of rimiterol aerosol, heart rate or blood pressure. The plasma terbutaline concentration in the morning of the seventh treatment day was significantly higher during SR-tablet treatment. The plasma terbutaline concentration curve showed a smaller peak/trough ratio for the SR-tablets.

Administration, Oral↗

Epsilon amino caproic acid myopathy: additional features.

In a patient with a proximal myopathy due to Epsilon Amino Caproic Acid (EACA) bedrest led to marked improvement even before withdrawal of the drug. A biopsy showed a selective necrosis of type I fibers. Plasma level of EACA was low and plasma level of lysine was normal. A 99mTechnetium-MDP showed marked uptake in the affected muscles, whereas a 67Gallium scan was negative.

Alanine Transaminase↗

Pulmonary disease due to Mycobacterium xenopi. Report of two cases.

Two patients with pulmonary disease due to M. xenopi are presented. Predisposing factors were alcoholism in one patient and previous tuberculosis with emphysema in the other. Whereas the disease was successfully treated in the first, M. xenopi was implicated as a contributory factor to death in the second. Histological examination in the latter case allowed no distinction from ordinary tuberculosis. A review of the literature suggests that infection with M. xenopi should be treated with a combination of rifampicin, isoniazid and one second-line drug, adjustments being made as results of sensitivity testing become available.

Aged↗